Quanterix Corp (OQ:QTRX)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 900 Middlesex Tpke
BILLERICA MA 01821-3929
Tel: N/A
Website: https://www.quanterix.com
IR: See website
Key People
E. Kevin Hrusovsky
Chairman of the Board, President, Chief Executive Officer
Amol Chaubal
Chief Financial Officer
David C. Duffy
Senior Vice President, Research & Development and Chief Technology Officer
Dawn R. Mattoon
Senior Vice President - Research Products
Mark T Roskey
Senior Vice President - Commercial and Accelerator
Business Overview
Quanterix Corporation develops ultra-sensitive digital immunoassay platform and tools for life science research and diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to detect protein biomarkers. The Company is also focusing to enable and develop novel therapies and diagnostics to facilitate in healthcare for earlier detection, monitoring, prognosis and, ultimately, prevention of disease. Simoa focuses on research and clinical testing applications and significantly advances enzyme-linked immunosorbent assay (ELISA) technology which is capable of unprecedented protein detection sensitivity. It also focuses on research and diagnostics for brain injuries, heart disease, cancer and other infectious diseases with its technology. The Company offers Simoa HD-1 analyzer, which is an automated immunoassay platform with multiplexing and custom assay capability.
Financial Overview
For the fiscal year ended 31 December 2019, Quanterix Corp revenues increased 51% to $56.7M. Net loss increased 29% to $40.8M. Revenues reflect Product revenue increase of 73% to $40.5M, Service Revenue increase of 33% to $16.1M. Higher net loss reflects Selling, General & Administrative Expens increase of 59% to $46.9M (expense), Stock-based Compensation in SGA increase of 29% to $5.3M (expense).
Employees: 248 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $380.32M as of Dec 31, 2019
Annual revenue (TTM): $56.74M as of Dec 31, 2019
EBITDA (TTM): -$38.59M as of Dec 31, 2019
Net annual income (TTM): -$40.80M as of Dec 31, 2019
Free cash flow (TTM): -$37.03M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 28,225,653 as of Mar 1, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization